title: Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience.
abstract: From 1990 to 1997, 16 consecutive patients with stage III and IVa invasive thymoma were treated in a single institution with primary chemotherapy consisting in adriamycin (40 mg m(-2)), cisplatin (50 mg m(-2)) administered intravenously on day 1, vincristine (0.6 mg m(-2)) on day 2 and cyclophosphamide (700 mg m(-2)) on day 4 (ADOC). The courses were repeated every 3 weeks. The aim was to evaluate the impact of this cytotoxic regimen with respect to response rate, per cent of patients radically resected, time to progression and overall survival. Two complete responses (one clinical and one pathological) and 11 partial responses were observed (overall response rate 81.2%); two patients had stable disease and one progressed. Toxicity was mild as only two patients developed grade III/IV neutropenia and one patient grade III nausea/vomiting. Nine patients were radically resected (five out of ten with stage III, and four out of six with stage IVa). Median time to progression and overall survival was 33.2 and 47.5 months respectively. Three patients were alive and disease free after more than 5 years. The ADOC scheme is highly active and manageable in the treatment of locally advanced thymoma. As a preoperative approach it should be offered to patients not amenable to surgery or to those surgically resectable but with a great deal of morbidity.
authors.affiliation: Dipartimento di Scienze Cliniche e Biologiche, Oncologia Medica, Università di Torino, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Berruti
authors.forename: P
authors.initials: P
authors.lastname: Borasio
authors.forename: A
authors.initials: A
authors.lastname: Gerbino
authors.forename: G
authors.initials: G
authors.lastname: Gorzegno
authors.forename: T
authors.initials: T
authors.lastname: Moschini
authors.forename: M
authors.initials: M
authors.lastname: Tampellini
authors.forename: F
authors.initials: F
authors.lastname: Ardissone
authors.forename: M P
authors.initials: MP
authors.lastname: Brizzi
authors.forename: A
authors.initials: A
authors.lastname: Dolcetti
authors.forename: L
authors.initials: L
authors.lastname: Dogliotti
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D013945:Thymoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D013953:Thymus Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin